Cyclooxygenase-2 and human epidermal growth factor receptor type 2 (HER-2) expression simultaneously in invasive and in situ breast ductal carcinoma. 2011

Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
Department of Gynecology and Obstetrics, Santa Casa de Misericórdia de São Paulo Hospital, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil. adrilucarelli@terra.com.br

OBJECTIVE Cyclooxygenase-2 (COX-2) and human epidermal growth factor receptor type 2 (HER-2) are associated with tumorigenesis. Studies have shown that HER-2 can regulate COX-2 expression. The aim of this study was to evaluate the correlation between COX-2 and HER-2 expression in normal breast epithelium and in ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) present in the same breast. METHODS Cross-sectional study at the Mastology Unit of the Department of Gynecology and Obstetrics, Santa Casa de Misericórdia de São Paulo Hospital. METHODS COX-2 and HER-2 were detected using immunohistochemistry on 100 tissue fragments. HER-2 > +2 was subjected to fluorescence in situ hybridization (FISH). RESULTS COX-2 expression was detected in 87%, 85% and 75% of IDC, DCIS and normal epithelium, respectively. HER-2 expression was detected in 34% of IDC and 34% of DCIS. COX-2 in DCIS correlated with HER-2 in IDC (P = 0.049) and DCIS (P = 0.049). COX-2 in normal epithelium correlated with HER-2 in IDC (P = 0.046) and DCIS (P = 0.046). COX-2 in IDC was not associated with HER-2 (P = 0.235). Comparison between COX-2 and HER-2 in DCIS showed that there was a statistically significant difference with regard to nuclear grades II and III and presence of comedonecrosis (P < 0.001). In IDC, there was significant expression with nuclear grades II and III and histological grade II (P < 0.001). CONCLUSIONS Our findings provide evidence that HER-2 and COX-2 regulate each other.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009336 Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002285 Carcinoma, Intraductal, Noninfiltrating A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma. Carcinoma, Intraductal,DCIS,Ductal Carcinoma In Situ,Atypical Ductal Hyperplasia,Intraductal Carcinoma, Noninfiltrating,Atypical Ductal Hyperplasias,Carcinoma, Noninfiltrating Intraductal,Carcinomas, Intraductal,Carcinomas, Noninfiltrating Intraductal,Ductal Hyperplasia, Atypical,Ductal Hyperplasias, Atypical,Hyperplasia, Atypical Ductal,Hyperplasias, Atypical Ductal,Intraductal Carcinoma,Intraductal Carcinomas,Intraductal Carcinomas, Noninfiltrating,Noninfiltrating Intraductal Carcinoma,Noninfiltrating Intraductal Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
April 2015, Annals of oncology : official journal of the European Society for Medical Oncology,
Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
September 2019, Journal of breast cancer,
Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
January 2007, The Kobe journal of medical sciences,
Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
March 2002, Cancer research,
Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
May 2002, Gynecologic oncology,
Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
October 2014, The American surgeon,
Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
January 2008, Frontiers in bioscience : a journal and virtual library,
Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
October 2002, Cancer research,
Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
December 2006, Annals of diagnostic pathology,
Adrienne Pratti Lucarelli, and Maria Marta Martins, and Wagner Montor, and Vilmar Oliveira, and Maria Antonieta Longo Galvão, and Sebastião Piato
June 2006, Breast (Edinburgh, Scotland),
Copied contents to your clipboard!